CD47 and neoplasm: Based on these findings, we hypothesized that pre-treatment with the agonistic RTX-IgG2 – which reduces the anti-phagocytic CD47 on the surface of target cells – could enhance the phagocytic efficacy of other tumor-targeting mAbs.